Biocon (BOM:532523) Net Income From Continuing Operations : ₹14,894 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Biocon Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Biocon's net income from continuing operations for the three months ended in Dec. 2023 was ₹7,533 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was ₹14,894 Mil.

Biocon Net Income From Continuing Operations Historical Data

The historical data trend for Biocon's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocon Net Income From Continuing Operations Chart

Biocon Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income From Continuing Operations

Get a 7-Day Free Trial

10,026.00

8,709.00

8,462.00

7,716.00

6,430.00

Biocon Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-207.00	4,145.00	1,489.00	1,727.00	7,533.00

Biocon Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14,894 Mil.

Biocon (BOM:532523) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (BOM:532523) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

BIOCON:India

Address

20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560 100

Website

https://www.biocon.com

Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Generics, Biosimilars, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene.

Biocon (BOM:532523) Headlines

No Headlines